CohBar to Announce 2021 First Quarter Financial Results and Provide Business Update on May 17, 2021
May 03 2021 - 9:00AM
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company
developing mitochondria based therapeutics to treat chronic
diseases and extend healthy lifespan, announced today that the
company will release its first quarter 2021 financial results after
the market closes on Monday, May 17, 2021. Management will host a
conference call with a slide presentation at 5:00 p.m. ET (2:00
p.m. PT) on the same day to provide an update on the company’s
business.
Details for the Conference Call and Slide
Presentation: Date: May 17, 2021Time: 5:00 p.m. ET (2:00
p.m. PT)
Conference Audio
- Dial-in U.S. and Canada: (877) 451-6152
- Dial-in International: (201) 389-0879
- Conference ID No.: 13718702
Slide Presentation
- Please visit
https://us02web.zoom.us/j/87546345875?pwd=UU1HK25QZmxmNS9tK21rSXUyUGQvUT09
and enter password CWBR, or
- Go to www.cohbar.com and click on Q1 2021 Shareholder
Presentation at the top of homepage.
- Please note, the conference audio will only be available by
dial-in and not through Zoom.
For individuals participating in the Investor Call and Slide
Presentation, please call into the conference audio and log into
Zoom approximately 10 minutes prior to its start.
An audio replay of the call will be available beginning at 8:00
p.m. Eastern Time on May 17, 2021, through 11:59 p.m. Eastern Time
on June 7, 2021. To access the recording please dial (844) 512-2921
in the U.S. and Canada, or (412) 317-6671 internationally, and
reference Conference ID# 13718702. The audio recording along with
the slide presentation will also be available at www.cohbar.com
during the same period.
About CohBar
CohBar (NASDAQ: CWBR) is a clinical stage biotechnology company
focused on the research and development of mitochondria based
therapeutics, an emerging class of drugs for the treatment of
chronic and age-related diseases. Mitochondria based therapeutics
originate from the discovery by CohBar’s founders of a novel group
of naturally occurring peptide sequences within the mitochondrial
genome, some of which have been shown to have the
potential to regulate key processes
in multiple systems and organs in the body. To date,
the company has discovered more than 100 mitochondrial derived
peptides and generated over 1,000 analogs. CohBar’s efforts focus
on the development of these peptides into therapeutics that offer
the potential to address a broad range of diseases associated
with the underlying impact of mitochondrial dysfunction. The
company’s lead compound, CB4211, is in the Phase 1b stage of a
Phase 1a/1b clinical trial for NASH and obesity. In addition,
CohBar has four preclinical programs: CB5138 Analogs for
fibrotic diseases, CB5064 Analogs for COVID-19 associated
ARDS, CB5046 Analogs for CXCR4-related cancer and orphan diseases,
and MBT3 Analogs for cancer immunotherapy.
For additional company information, please visit
www.cohbar.com.
Contacts:
Jordyn TaraziDirector of Investor RelationsCohBar, Inc.(650)
445-4441Jordyn.tarazi@cohbar.com
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Jun 2024 to Jul 2024
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Jul 2023 to Jul 2024